ClinicalTrials.gg
RecruitingNCT07862101CARES-T1DUpdated Oct 7, 2026

Strategy For Assessing The Risk Of Type 1 Diabetes In Pediatric Celiac Patients

An observational study in Diabete Type 1, sponsored by University of Bari. Recruiting at 1 site in Italy. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Bari · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Celiac Disease with a site in Italy — 14 open to participants now, 16 under way, none of them phase 3. Celiac Disease · Italy.

Planned enrollment
3rd of 26
600 · median 207
Started
2026
with 2 others
Observational
26 of 61
9 open now
Primary completion
2026-12
later than 8 of 15 live
Registered
58th of 61
by date
Lead sponsor
2 of 61
University of Bari

Among the 61 studies in Celiac Disease with a site in Italy, this one is the 3rd largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2026, is one of 26 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 58th registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

14 of the 61 studies in Celiac Disease with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Celiac Disease with a site in Italy, or all of them as a file.
02

Study summary

Celiac disease (CD) and type 1 diabetes mellitus (T1D) are chronic autoimmune disorders that frequently co-occur, largely due to shared genetic susceptibility, particularly HLA-DQ2 and HLA-DQ8 alleles. In Italy, approximately 300,000 individuals are affected by T1D, with a prevalence of 0.5% in the general population and 0.22% in the pediatric population. The annual incidence among children is 12.26 per 100,000, with boys affected more frequently than girls (13.13 vs. 11.35 per 100,000). Alarmingly, 25-40% of pediatric patients present with diabetic ketoacidosis (DKA) at disease onset. International prospective studies, such as the Environmental Determinants of Diabetes in the Young (TEDDY) study, have demonstrated that symptoms are poor predictors of CD autoimmunity, emphasizing the need for structured population-based screening strategies. Similarly, in T1D, the appearance of disease-specific autoantibodies-such as anti-GAD, insulin autoantibodies (IAA), IA-2A, and ZnT8A-can precede the onset of clinical disease by years. Identifying these markers enables early risk stratification, timely monitoring, and potential enrollment in immunomodulatory prevention trials, including those organized by TrialNet.

In this context, an observational study is being conducted at the Pediatric Department of the University of Bari. It involves the prospective screening of children (ages 1 to 18 years) with a confirmed diagnosis of celiac disease for T1D-associated autoantibodies. The study aims to enroll 600 CD patients over one year, with an anticipated 80% participation rate among eligible families.

Read the detailed description

Celiac disease (CD) and type 1 diabetes mellitus (T1D) are chronic autoimmune disorders that frequently co-occur, largely due to shared genetic susceptibility, particularly HLA-DQ2 and HLA-DQ8 alleles. In Italy, approximately 300,000 individuals are affected by T1D, with a prevalence of 0.5% in the general population and 0.22% in the pediatric population. The annual incidence among children is 12.26 per 100,000, with boys affected more frequently than girls (13.13 vs. 11.35 per 100,000). Alarmingly, 25-40% of pediatric patients present with diabetic ketoacidosis (DKA) at disease onset.

Current guidelines recommend screening for celiac disease with tissue transglutaminase autoantibody (TGA) testing in both symptomatic individuals and asymptomatic individuals with high-risk features. These include a family history of CD, coexisting autoimmune disorders such as T1D, and specific genetic syndromes. While gastrointestinal symptoms like diarrhea, abdominal distension, vomiting, and malabsorption often prompt CD evaluation, many patients-more than half-are asymptomatic at diagnosis. This highlights a significant limitation in symptom-based screening approaches.

International prospective studies, such as the Environmental Determinants of Diabetes in the Young (TEDDY) study, have demonstrated that symptoms are poor predictors of CD autoimmunity, emphasizing the need for structured population-based screening strategies. Similarly, in T1D, the appearance of disease-specific autoantibodies-such as anti-GAD, insulin autoantibodies (IAA), IA-2A, and ZnT8A-can precede the onset of clinical disease by years. Identifying these markers enables early risk stratification, timely monitoring, and potential enrollment in immunomodulatory prevention trials, including those organized by TrialNet.

In this context, an observational study is being conducted at the Pediatric Department of the University of Bari. It involves the prospective screening of children (ages 1 to 18 years) with a confirmed diagnosis of celiac disease for T1D-associated autoantibodies. The study aims to enroll 600 CD patients over one year, with an anticipated 80% participation rate among eligible families. This initiative seeks to identify early serological markers of T1D in a high-risk population and to inform preventive strategies aimed at reducing the burden of severe complications such as DKA.

03

Conditions studied

  • Diabete Type 1

Browse trials for

Keywords

  • diabete type 1
  • celiac disease
  • paediatric patients
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children with biopbsy-confirmed CD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 1-18 years with -confirmed CD.
  • from parents/legal guardians and assent from the child (as applicable).

Exclusion criteria

Exclusion Criteria:

    • Known diagnosis of type 1 diabetes.

      • Other endocrinopathies or therapy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Celiac paediatric patients

    600 pediatric subjects will be enrolled, all with a confirmed diagnosis of celiac disease according to the 2020 ESOPGHAN criteria.

06

What researchers measure

Primary outcomes

  1. Screening of celiac paediatric patients

    The aim of the CARES-T1D project is to determine the prevalence of type 1 diabetes-associated autoantibodies (T1D) in pediatric subjects with CD to assess the frequency with which these immunologic biomarkers occur in this specific population. The plan is to screen all children in follow-up at our out-patient celiac clinic for diabetes specific autoantibodies. The parents will be informed about the study and invited to take part in the study during the scheduled appointment; a written informed consent will be signed by parents. The screening activity will be carried out over a 1-year period. It is expected that at least 80% of the parents will give their informed consent to participation in the study. Accordingly, about 480 celiac patients will be screened for the four biochemical autoantibodies predicting T1D, i.e. insulin autoantibodies (IAA)

    Time frame: baseline

Secondary outcomes

  1. TD1 in CD

    Secondary aims are a) to assess the frequency of multiple autoantibody positivity and classify children according to TrialNet T1D staging; b) to identify predictors of antibody positivity; c) to evaluate progression rates to clinical T1D in the follow-up phase; d) to reduce the incidence of DKA by promoting early detection; d) to validate a scalable screening protocol for T1D risk in pediatric CD populations.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • University Of Bari Aldo Moro-Pediatric Gastroenterology Section
    Bari, BA 70121, Italy
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 48 observational studies under Celiac Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 83. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Oct 7, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862101
Lead sponsor
University of Bari
Responsible party
Ruggiero Francavilla (Professor, University of Bari) — Principal investigator
First posted
Oct 7, 2026
Start date
Jan 1, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

Ruggiero Francavilla, Prof
Contact
rfrancavilla@gmail.com
00390805592063
Fernanda Cristofori, MD
Contact
fernandacristofori@gmail.com
00393384176598

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion